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Ectodysplasin target gene Fgf20 
regulates mammary bud growth 
and ductal invasion and branching 
during puberty
Teresa Elo1, Päivi H. Lindfors1, Qiang Lan1, Maria Voutilainen1, Ewelina Trela1, Claes Ohlsson2, 
Sung-Ho Huh3,6, David M. Ornitz3, Matti Poutanen4, Beatrice A. Howard5 & Marja L. Mikkola1
Mammary gland development begins with the appearance of epithelial placodes that invaginate, 
sprout, and branch to form small arborized trees by birth. The second phase of ductal growth and 
branching is driven by the highly invasive structures called terminal end buds (TEBs) that form at ductal 
tips at the onset of puberty. Ectodysplasin (Eda), a tumor necrosis factor-like ligand, is essential for 
the development of skin appendages including the breast. In mice, Eda regulates mammary placode 
formation and branching morphogenesis, but the underlying molecular mechanisms are poorly 
understood. Fibroblast growth factor (Fgf) receptors have a recognized role in mammary ductal 
development and stem cell maintenance, but the ligands involved are ill-defined. Here we report 
that Fgf20 is expressed in embryonic mammary glands and is regulated by the Eda pathway. Fgf20 
deficiency does not impede mammary gland induction, but compromises mammary bud growth, as well 
as TEB formation, ductal outgrowth and branching during puberty. We further show that loss of Fgf20 
delays formation of Eda-induced supernumerary mammary buds and normalizes the embryonic and 
postnatal hyperbranching phenotype of Eda overexpressing mice. These findings identify a hitherto 
unknown function for Fgf20 in mammary budding and branching morphogenesis.
Mammalian fibroblast growth factors (Fgfs) constitute a family of 18 secreted polypeptide growth factors with 
diverse roles in multiple developmental processes1. Secreted Fgfs serve as ligands for single-pass transmembrane 
receptor tyrosine kinases (Fgfr1–4). With the exception of Fgfr4, alternative splicing of Fgfrs produces two iso-
forms (IIIb and IIIc isoforms) with different ligand binding specificities. In general, mesenchymal Fgfs encage 
epithelial IIIb receptor isoforms, whereas epithelial Fgfs signal to mesenchymal IIIc receptors2. Activation of any 
of these isoforms can trigger several signalling cascades including the RAS-MAPK, PI3K, STAT, and PLCγ path-
ways leading to various cellular responses in a context dependent manner. The fact that all Fgfs can bind to several 
Fgfrs, and vice versa, produces a high degree of redundancy within the system1.
Mammary gland development proceeds via distinct stages: the hormone-independent embryonic and prepu-
bertal morphogenesis, and the subsequent pubertal, pregnancy, lactation, and involution stages driven by hor-
monal cues3. In mice, mammary gland development commences at ~embryonic day 11 (E11) with the sequential 
appearance of five pairs of mammary primordia called placodes4. Placodes are local epithelial thickenings that 
gradually invaginate to the underlying tissue to form buds, which from E12.5 onwards are surrounded by a spe-
cialized condensed mammary mesenchyme. Mammary buds grow relatively slowly in size until E15–E16 when a 
primary sprout forms. The sprout invades the secondary mammary mesenchyme, the precursor of the fatty adult 
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stroma, and branching morphogenesis begins. By birth (E19–E20), a small ductal tree with 10–15 branches has 
formed. Nipple sheath, as well as lumen formation also start at late embryogenesis4.
Postnatal growth and branching is relatively slow until the onset of puberty, which begins at ~3 week of age 
as a response to onset of ovarian steroid hormone production and is associated with remarkable morphological 
changes. Bulbous epithelial structures called terminal end buds (TEBs) form at the tips of mammary ducts and 
start invading into the fat pad3. This phase of rapid growth, which includes extensive ductal elongation, branch-
ing, and extracellular matrix (ECM) degradation, continues until the ductal network reaches the borders of the 
fat pad and the TEBs regress by the age of 10–12 weeks5.
Mammary gland morphogenesis relies on sequential and reciprocal crosstalk between the epithelium and the 
underlying stroma and these tissue interactions guide all aspects of mammary gland development from induction 
to involution6. This crosstalk is mediated by conserved signaling pathways, of which the Wnt and Fgf pathways 
are the most critical ones during the early stages of mammogenesis7, 8. Loss of the Wnt signal mediator Lef1 
leads to absence of placodes 2 and 39, whereas epithelial overexpression of the soluble Wnt inhibitor Dkk1 pre-
vents mammary placode formation altogether10. Deficiency in Fgf10 or its receptor Fgfr2b blocks induction of 
all mammary placodes except the fourth11. The initiation of bud outgrowth is triggered by epithelially expressed 
parathyroid hormone related peptide (PTHrP, a.k.a. parathyroid hormone like hormone): mice null for PTHrP 
or its mesenchymal receptor (Pth1r) display little to no bud sprouting12. Disruption of canonical Wnt signaling 
pathway components, such as Lrp6 results in stunted embryonic branching morphogenesis and underdeveloped 
fat pad13. Ductal growth and branching is also compromised, albeit to a lesser extent, in epidermal growth factor 
receptor (Egfr) null neonates14.
Pubertal branching morphogenesis is regulated by systemic hormones, especially estradiol and growth hor-
mone (GH)3, 15. A critical factor induced by estrogen receptor α (Esr1) in the mammary epithelium is the Egf 
family member amphiregulin (Areg), which activates stromal Egfr signaling16–18. Accordingly, Areg and Esr1 
knockout mice display a highly similar pubertal phenotype characterized by failure in TEB formation and ductal 
elongation18–20. GH signalling is essential in the mammary stroma where its effects are mediated by insulin-like 
growth factor 1 (Igf-1), which in turn promotes epithelial cell proliferation and survival3. Both GH receptor and 
Igf-1 null mice exhibit greatly limited ductal outgrowth21, 22. In addition, several other signaling molecules regu-
late ductal morphogenesis during puberty although their link to hormone signaling is less clear3, 23.
Also Fgf signaling plays an important role in mammary branching morphogenesis, as well as in maintaining 
homeostasis in the adult. Thus far, functional studies have focused on epithelial Fgfrs, in particular Fgfr2b, or 
their stromal ligands. The single pair (bud 4) of Fgf10 null mammary primordia sprouts, but shows either absent 
or very rudimentary ramifications11. Several studies have demonstrated the crucial role of Fgfr2 signaling in 
postnatal development including induction and maintenance of the TEBs, and in ability of mammary stem cells 
to repopulate the fat pad in transplantation assays24–27. Furthermore, conditional epithelial deletion of Fgfr1 leads 
to a ductal outgrowth phenotype, albeit transient, which is evident already at the onset of puberty26.
Ectodysplasin-A1 (hereafter Eda), a member of the tumor necrosis factor (Tnf) superfamily has recently 
emerged as an important regulator of mammary gland development. Eda signaling is mediated via its receptor 
Edar and culminates in the activation of the transcription factor NF-κB28. Eda pathway loss- and gain-of-function 
mouse models have been highly informative in elucidating the role of this pathway in mammary gland biol-
ogy29–31. Eda is dispensable for mammary placode formation, yet Eda-overexpressing (K14-Eda) mice develop 
supernumerary mammary glands along and anterior to the milk line29, 32, 33. Deficiency in Eda, Edar, or NF-κB 
leads to smaller ductal trees, a phenotype that manifests from embryogenesis up to at least 6 weeks of age. The 
converse is observed in Eda and Edar overexpressing mice30, 34. In humans, inactivating mutations in the Eda 
pathway genes cause a syndrome characterized by defective development of several ectodermal organs including 
the breast35, 36. In order to identify the transcriptional mediators of Eda/Edar/NF-κB, we performed microarray 
profiling of embryonic Eda null mammary buds after a 4-hour ex vivo exposure to control medium or recombi-
nant Eda protein. This screen revealed several putative Eda target genes including Fgf2033, a member of the Fgf9 
subfamily comprising of Fgf9, Fgf16, and Fgf201. Our previous studies have identified Fgf20 as an important 
downstream effector of Eda in developing hair follicles and teeth37–39. The present study unveiled an important 
role for Fgf20 in mammogenesis.
Results
Fgf20 is expressed in the embryonic mammary buds. We have previously shown by microarray pro-
filing that a short treatment with recombinant Eda protein upregulates the expression of Fgf17 and Fgf20 in the 
mammary buds of E13.5 Eda−/− embryos ex vivo33. Quantitative RT-PCR was used to validate these findings, as 
well as the expression of Fgf4 and Fgf9, two Fgf family members reported to be expressed in the mammary buds40 
but not upregulated by Eda in the microarray. In line with the microarray results, after 4 hours Eda-treatment, of 
these only Fgf17 and Fgf20 were upregulated 5.8-fold (p = 0.042) and 3.8-fold (p = 0.019), respectively (Fig. 1a). 
However, analysis of the absolute mRNA quantity indicated that Fgf17 is expressed at a very low level, and thus 
the role of Fgf17 in mammary gland development was not analyzed further.
In order to analyze expression of Fgf20 in embryonic mammary glands, we took advantage of the Fgf20-LacZ 
knock-in allele41 and performed X-gal staining on Fgf20LacZ/+ embryos between E10.5 and E18.5. Expression of 
Fgf20-LacZ was detected earliest at ~E11.25 in the mammary bud 1 (data not shown), and at E11.5 in the buds 
1 and 3 (Fig. 1b). At E13.5, Fgf20-LacZ expression was detected in all mammary buds (Fig. 1b) and accordingly, 
in situ hybridization with an Fgf20 specific probe showed positive signal in wildtype embryos at the same stage 
(Fig. 1d). The Fgf20-LacZ expression was still relatively strong in the mammary buds at E15.5 (Fig. 1e) but was 
substantially downregulated at E16.5 (Fig. 1f,g). At E18.5, no expression of Fgf20-LacZ could be detected in the 
mammary glands by X-gal staining (Fig. 1h) or immunohistochemical staining with anti-β-galactosidase anti-
body, although expression in hair follicles was readily observed (Fig. S1a), as reported previously39. At postnatal 
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stages, expression of Fgf20-LacZ was assessed by X-gal staining and anti-β-galactosidase antibody in mammary 
glands of 3-, 5- and 7-week-old Fgf20LacZ/+ and Fgf20LacZ/LacZ mice, and by qRT-PCR in samples from 3 different 
regions (proximal to nipple, middle, and distal to nipple) of 5-week old glands. No expression was detected in the 
postnatal mammary gland by any of the methods used (Supplementary Fig. S1).
Eda levels influence the expression of Fgf20 in vivo. The observation that Eda induced the expression 
of Fgf20 in the embryonic mammary buds ex vivo prompted us to study the influence of Eda on Fgf20 expression 
levels in vivo by analyzing the Fgf20-LacZ expression in Eda null and Eda-overexpressing (K14-Eda) embryos. 
In Eda−/− embryos there was a slight delay in the onset of Fgf20-LacZ expression at E11.5 followed by somewhat 
decreased signal at E12.5 compared to control or K14-Eda embryos (Fig. 2a,b). At E13.5–E14.5 expression in 
K14-Eda embryos appeared more intense (Fig. 2c,d), and at E15.5, Fgf20-LacZ expression levels correlated with 
the Eda status (Fig. 2e). Together, these data show that loss- and gain- of Eda influence Fgf20-LacZ expression, 
Figure 1. Fgf20 is induced by Eda and is expressed in embryonic mammary glands. (a) qRT-PCR analysis of 
Fgf4 (n = 4), Fgf 9 (n = 4), Fgf17 (n = 6) and Fgf20 (n = 7) expression in E13.5 Eda−/− mammary buds after 
4 h treatment with Eda protein ex vivo. Values represent mean ± SD. (b,c) X-gal-stained whole mounts of 
Fgf20LacZ/+ embryos at E11.5 (b) and E13.5 (c) showing positive staining in the developing mammary buds 
(numbered). (d) In situ hybridization of a WT embryo with an Fgf20 specific probe at E13.5. (e,f) X-Gal 
stained whole mount of E15.5 whole embryo (e) and dissected skin of E16.5 embryo (f) showing staining in the 
developing mammary buds (numbered) and hair follicles. (g,h) Representative figures of histological sections of 
X-Gal whole mount-stained mammary glands of Fgf20LacZ/+ embryos at E16.5 (g) and E18.5 (h). *p < 0.05. At 
least two litters of Fgf20LacZ/+ embryos per stage were analyzed. *p < 0.05. mb, mammary bud.
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although modestly, yet clearly cues other than Eda have a more prominent impact on Fgf20 expression during 
embryogenesis. The Wnt pathway is the most likely positive regulator: the murine Fgf20 promoter is known to be 
highly responsive to β-catenin/Lef1 in promoter-reporter assays39.
Absence of Fgf20 compromises mammary bud formation. To elucidate the role of Fgf20 in mam-
mary gland development, we first analyzed the expression of placode markers Wnt10b and PTHrP by RNA in situ 
hybridization in the mammary buds of Fgf20LacZ/+ and Fgf20LacZ/LacZ mice (Figs 3 and 4). At 46–48 somite stage 
(E11.5–E11.75) Wnt10b expression in the two genotypes was indistinguishable indicating that Fgf20 deficiency 
does not impede induction of mammary gland development (Fig. 3a). At E12.5, however, Wnt10b expression 
domain appeared smaller in Fgf20LacZ/LacZ embryos, the difference being most pronounced in bud 3 (Fig. 3b), 
which is the first bud to form11. Quantification of the Wnt10b expression domain confirmed a significant differ-
ence between the two genotypes (p = 0.0007) (Fig. 3b’). At E13.5, the same was observed with the PTHrP probe, 
or when Fgf20-LacZ expression was assessed by X-gal staining (Fig. 4). For a more detailed morphological anal-
ysis, EpCAM-stained mammary buds 3 were visualized by whole mount confocal microscopy in 3D (Fig. 3c,d). 
Quantification revealed that Fgf20LacZ/LacZ buds were substantially smaller than control buds at E13.5 (p = 1.098E-
13) and E15.5 (p = 2.234E-6). In attempt to gain insights into the molecular mechanisms underlying the Fgf20LacZ/
LacZ bud phenotype, we analyzed expression of Edar, Lef1, and Dkk4 at E12.5, and Lef1 protein at E13.5. No gross 
difference in Edar, or Lef1 expression was detected, but Dkk4 expression was somewhat reduced in Fgf20LacZ/LacZ 
embryos (Supplementary Fig. S2), as previously shown in hair placodes (Huh et al.39).
The appearance of supernumerary mammary placodes between the endogenous buds 3 and 4 in K14-Eda 
mice has been shown at E12.5 by a number of Wnt pathway genes, and at E13.5 they are clearly visible by various 
Figure 2. The influence of loss (Eda−/−) and gain of Eda (K14-Eda) on the expression of Fgf20-LacZ in 
embryonic mammary glands. (a,b) Whole-mount X-Gal staining of Eda−/−;Fgf20LacZ/+; Eda+/+;Fgf20LacZ/+, and 
K14-Eda;Fgf20LacZ/+ embryos at E11.5 and E12.5. (c–e) Histological sections of whole mount X-Gal stained 
mammary buds at E13.5 (mb2), E14.5 (mb2), and E15.5 (mb3).
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mammary bud markers including PTHrP29, 33, 34. At E13.5 PTHrP was not detected between bud 3 and 4 in 
K14-Eda;Fgf20LacZ/LacZ embryos in contrast to K14-Eda;Fgf20LacZ/+ embryos (Fig. 4a). Furthermore, stereomi-
croscopic inspection, as well as X-gal staining and subsequent analysis of histological sections suggested the 
absence of supernumerary mammary buds in the K14-Eda;Fgf20LacZ/LacZ mice at E13.5 (Fig. 4b). However, based 
on similar analyses, supernumerary mammary buds were detectable in K14-Eda;Fgf20LacZ/LacZ embryos slightly 
later, at ~E14.0 (Supplementary Fig. S3). Accordingly, supernumerary nipples were observed on the milk line and 
the neck region of pre- and post-pubertal K14-Eda;Fgf20LacZ/LacZ females (Supplementary Fig. S3). As previously 
reported for K14-Eda males34, also K14-Eda;Fgf20LacZ/+ and K14-Eda;Fgf20LacZ/LacZ males had supernumerary 
Figure 3. Fgf20 deficiency does not impede placode induction but compromises bud growth. (a) Expression 
of Wnt10b at somite stage 46–48 (Fgf20LacZ/+, n = 7; Fgf20LacZ/LacZ, n = 7) and (b) E12.5 (Fgf20LacZ/+, n = 6; 
Fgf20LacZ/LacZ, n = 6), and (b’) quantification of Wnt10b expression area (mammary bud 3) at E12.5. (d,e) 3D 
images and volume quantifications of EpCAM-stained mammary bud 3 at E13.5 (Fgf20LacZ/+, n = 24; Fgf20LacZ/
LacZ, n = 28), and E15.5 (Fgf20LacZ/+, n = 8; Fgf20LacZ/LacZ, n = 13). The bud contours were outlined manually 
(purple) for volume quantification. ***p < 0.001; ****p < 0.0001.
Figure 4. Fgf20 deficiency delays induction of supernumerary buds in K14-Eda mice. (a) Expression of PTHrP 
at E13.5 (Fgf20LacZ/+, n = 4; Fgf20LacZ/LacZ, n = 4; K14-Eda;Fgf20LacZ/+, n = 7; K14-Eda;Fgf20LacZ/LacZ, n = 5), and 
(b) X-gal staining of Fgf20-LacZ at E13.5 (Fgf20LacZ/+, n = 4; Fgf20LacZ/LacZ, n = 6; K14-Eda;Fgf20LacZ/+, n = 11; 
K14-Eda;Fgf20LacZ/LacZ, n = 8). Supernumerary placodes (stars) were detected between buds 3 and 4 in K14-
Eda;Fgf20LacZ/+ embryos at E13.5, but not in K14-Eda;Fgf20LacZ/LacZ embryos.
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nipples, and at least in the neck region, a ductal tree was readily observed in compound mutants (Supplementary 
Fig. S3). In conclusion, in the absence of Fgf20, all mammary buds formed, yet a clear reduction in bud size and a 
slight delay in appearance of supernumerary mammary buds in K14-Eda embryos was evident.
Absence of Fgf20 delays ductal growth in puberty. Macroscopic analysis of pubertal and adult 
Fgf20LacZ/LacZ females revealed the presence of the normal number of nipples. To examine the impact of Fgf20 defi-
ciency on postnatal mammary morphogenesis, 4th mammary glands of 5-week-old WT and Fgf20 LacZ/LacZ were 
analyzed (Fig. 5a–c). The number of the ductal ends was reduced by 35% (p = 0.018) and TEBs by 51% (p = 0.008) 
in Fgf20 LacZ/LacZ mice compared to WT controls (Fig. 5d,e). Also, the extent of ductal outgrowth (i.e. penetration 
to the fat pad) was significantly compromised (p = 0.037) (Fig. 5f). These data clearly show that absence of Fgf20 
greatly retards ductal outgrowth during puberty. The ductal characteristics were, however, quite variable among 
the Fgf20 LacZ/LacZ mice: often the ductal tree was very rudimentary and barely contained any TEBs while in some 
mice the ductal tree was only modestly affected (Fig. 5a–c). Quantification of the maximum width of the five 
largest TEBs/ductal tips in each specimen confirmed a significant difference between Fgf20LacZ/LacZ and WT mice 
(p = 0.029) (Fig. 5g). Ki-67 expression analysis in TEBs evidenced a decrease in the number of proliferating cells 
in Fgf20 mutants (p = 0.0038) (Fig. 5h,i).
No evidence for a systemic pubertal defect in Fgf20LacZ/LacZ females. We detected Fgf20 expression 
only in the embryonic mammary glands (see above), yet Fgf20LacZ/LacZ mammary glands displayed a remarkable 
postnatal phenotype (Figs 5 and 6). To assess whether the pubertal phenotype could be caused by a systemic 
defect due to the germline deletion of the Fgf20 gene, we analyzed various parameters in the mutant animals. We 
found no difference in the onset of puberty, nor in the weight of the animals at the onset of, or during puberty 
(at 3, 5, or 7 weeks of age), or the weight of ovaries and uteri (Supplementary Fig. S4). Yet, 18% of 7-week-old 
Fgf20LacZ/LacZ females (n = 22) had completely closed vaginas, whereas a similar defect was not observed in WT 
mice (n = 9). These mice were not used for mammary gland analyses. The estrus cycles analyzed from vagi-
nal smear cytology of WT and Fgf20LacZ/LacZ females were normal, and serum estradiol levels of the 7-week-old 
Fgf20LacZ/LacZ females in diestrus were similar to those of WT littermates (Supplementary Fig. S4). Finally, we 
performed mammary fat pad transplantations in which 1 mm3 pieces of adult Fgf20+/+ mammary glands were 
transplanted into the cleared fat pad of 3-to-4-week old WT or Fgf20LacZ/LacZ females and allowed to grow for 5 
weeks before analysis. WT epithelium grew equally well in the fat pad of both recipients (Supplementary Fig. S4). 
Collectively, these data indicate that there is no gross systemic defect in Fgf20LacZ/LacZ females, which could explain 
the pubertal mammary phenotype.
Absence of Fgf20 normalizes the hyperbranching phenotype of K14-Eda mice. Our data show-
ing that Fgf20 expression levels are modulated by Eda (Fig. 1) and loss of Fgf20 delays ductal growth at puberty 
(Fig. 5) prompted us to study the effects of Fg20 deficiency on ductal branching at other developmental stages, 
as well as the crosstalk with the Eda pathway. At E18, the number of ductal ends in the mammary glands of 
Fgf20LacZ/LacZ embryos was similar to that of wildtype mice (p = 0.638) (Fig. 6a,a’). However, mammary glands 
of 3-week-old Fgf20LacZ/LacZ mice contained somewhat lower number of ductal tips than those of WT controls 
(p = 0.0321) (Fig. 6b,b’). At 7 weeks of age, the decrease in the ductal outgrowth and number of ductal ends in 
Fgf20LacZ/LacZ mice was prominent (p = 0.0039 and p = 0.0051, respectively) (Fig. 6c,c’,e), even more pronounced 
than at 5 weeks of age (Fig. 5d). However, at 12 weeks of age, the number of ductal ends was similar in both gen-
otypes (p = 0.363) (Fig. 6d,d’).
Consistent with our previous results34, the number of ductal ends was significantly higher in K14-Eda mice 
compared to WT controls at E18 (p = 0.00009) and 3 weeks of age (p = 0.0019) (Fig. 6a,a’,b,b’). The hyperbranch-
ing phenotype was apparent also at 7 (p = 0.034) and 12 weeks of age (p = 0.0004) (Fig. 6c,c’,d,d’). Surprisingly, 
even though Fgf20 null mammary glands did not display a growth phenotype at E18, the K14-Eda phenotype 
was greatly attenuated in Fgf20LacZ/LacZ background (p = 0.0005) (Fig. 6a’). Also at later stages, loss of Fgf20 nor-
malized the K14-Eda phenotype, although at 7 weeks of age, the difference did not reach statistical significance 
(p3wk = 0.0046; p7wk = 0.1521, p12wk = 0.0011). These data identify Fgf20 as a critical mediator of Eda in mammary 
ductal growth and branching.
At late puberty, the terminal end buds of Fgf20LacZ/LacZ mice are larger and more proliferative. 
Since the growth delay of the Fgf20 mutants was most pronounced at 7 weeks of age, we analyzed the ducts and 
TEBs of Fgf20LacZ/LacZ and WT glands in more detail at this stage. The architecture of the ducts appeared normal 
based on all criteria used: histology, hormone receptor expression, the distribution of basal (K14) and luminal 
(K8) keratins, and the expression of basal cell marker α-SMA (Supplementary Fig. S5). Accordingly, FACS anal-
ysis did not show significant differences in the percentage of luminal (CD29loCD24+) or basal (CD29hi CD24+) 
cells between WT and the Fgf20LacZ/LacZ mice at 7 week of age, nor at 3 weeks when the growth phenotype was first 
evident (Supplementary Fig. S5).
Analysis of TEBs, however, revealed that the epithelium appeared more cellular in Fgf20LacZ/LacZ mice com-
pared to WT mice (Fig. 7a). TEB area, measured from the carmine alum whole mount images, was larger in 
Fgf20LacZ/LacZ mice at the same age (Fig. 7b). Quantification of Ki-67 and cleaved caspase-3 positive cells in TEBs 
revealed that the proportion of the proliferating cells was significantly higher in Fgf20LacZ/LacZ mice compared to 
WT controls (Fig. 7c,c’), but there was no difference in the proportion of apoptotic cells (Fig. 7d,d’). ERα and 
PR expression was indistinguishable between WT and Fgf20LacZ/LacZ TEBs (Fig. 7e,f). TEBs consist of a mass of 
luminal K8+ body cells surrounded by α-SMA+/p63+ cap cell layer. The expression patterns of body and cap 
cell markers were unchanged in 7-week old Fgf20LacZ/LacZ mice (Fig. 7g–i) indicating intact TEB architecture and 
cell identities.
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Discussion
In the current study, we have unveiled a role for Fgf20 in two stages of embryonic mammary gland develop-
ment: budding and branching morphogenesis. Even though Fgf20 was dispensable for mammary placode 
induction, the buds were smaller in size. The molecular mechanism underlying the bud growth defect remain 
elusive. Furthermore, loss of Fgf20 delayed, but did not prevent, the formation of supernumerary mammary 
buds in K14-Eda embryos. Perinatally, Fgf20 null mammary glands did not differ from the WT controls, yet 
the K14-Eda hyperbranching phenotype was greatly attenuated in Fgf20 null background. The most plausible 
Figure 5. Fgf20 deficiency compromises TEB formation and ductal invasion. (a–c) Carmine alum stained 
ductal trees of the 4th mammary gland (a,b) and histology of TEBs (c) of WT and Fgf20LacZ/LacZ mice at 5 weeks 
of age. (d–g) Quantification of the ductal ends (d), TEBs (e), ductal outgrowth (measured as the distance of 
furthest grown ductal end from the center of the lymph node) (f), and width of five biggest ductal ends in each 
gland (f) in WT (n = 6) and Fgf20LacZ/LacZ (n = 10) mice. (h, i) Immunohistochemical staining and quantification 
of Ki-67 -positive cells in TEBs of WT (n = 4) and Fgf20LacZ/LacZ (n = 3) mice. Total number of TEBs analyzed 
was n = 15 (WT), n = 9 (Fgf20LacZ/LacZ). Bars show mean ± SD. *p < 0.05; **p < 0.01.
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explanation for these seemingly contradictory findings is redundancy of Fgf20 with other Fgf ligands, the 
most prominent candidate being Fgf9, a member of the same Fgf subfamily. Fgf9 is expressed in embryonic 
mammary glands40, shares similar biochemical properties with Fgf20 including receptor specificity1, 2, and 
redundancy between these two Fgfs has already been demonstrated in developing teeth38, kidney42, and coch-
lea43. Other Fgfs reported to be expressed in mammary bud epithelium are Fgf4, Fgf8, and Fgf1740, which may 
further compensate for loss of Fgf20.
Fgf signaling typically mediates crosstalk across tissue compartments1, but whether the effects of Fgf20 on 
mammary gland epithelium are direct, mediated by the stroma, or both, is currently unknown. Fgf20 prefer-
entially, but not exclusively, activates the mesenchymally expressed IIIc receptors isoforms1, 2. In the developing 
Figure 6. Loss of Fgf20 attenuates the K14-Eda hyperbranching phenotype. (a–d) Carmine alum stained 4th 
mammary gland of WT, Fgf20LacZ/LacZ, K14-Eda, and K14-Eda;Fgf20LacZ/LacZ mice at E18 (a), 3 weeks (b), 7 weeks 
(c), and 12 weeks of age (d). (a’–d’) Quantification of the total number of end ducts (a’,b’) or end ducts past the 
lymph node (c’,d’) in 4th mammary gland. Number of glands analyzed were: WT (nE18 = 5, n3wk = 18, n7wk = 12, 
n12wk = 15) Fgf20LacZ/LacZ (nE18 = 8, n3wk = 16, n7wk = 28, n12wk = 5), K14-Eda (nE18 = 7, n3wk = 8, n7wk = 7, 
n12wk = 13) and K14-Eda;Fgf20LacZ/LacZ (nE18 = 6, n3wk = 8, n7wk = 9, n12wk = 10) (e) Ductal outgrowth (mm) 
measured from center of the lymph node in Fgf20+/+ (nglands = 7) and Fgf20LacZ/LacZ (nglands = 23). Data are shown 
as mean ± SD. ***p < 0.001; **p < 0.01; *p < 0.05; NS, not significant.
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cochlea, epithelially expressed Fgf20 positively regulates epithelial progenitor proliferation via the mesenchyme, 
whereas intraepithelial Fgf20 signaling is essential for sensory cell differentiation41, 43. In hair follicles, Fgf20 is 
dispensable for placode formation, but is necessary for condensation of the underlying mesenchymal cells, which 
in turn is required for further follicular downgrowth39. The target genes regulated by Fgf20 have remained elusive 
in all organs studied so far.
We have previously shown that Eda regulates expression of Fgf20 in embryonic hair follicles and teeth where 
Fgf20 functions as one of the major downstream effectors of the Eda pathway38, 39. Here, we identify Fgf20 as a 
mediator of Eda in the developing mammary glands: absence of Fgf20 delayed formation of supernumerary buds 
and normalized the hyperbranching mammary phenotype of K14-Eda mice, an effect maintained until adult-
hood. However, our data implicate the existence of other downstream targets of Eda besides Fgf20, since at E18 
and at the onset of puberty, the ductal trees of Eda-null mice are more severely affected than those of Fgf20LacZ/LacZ 
mice34. Our earlier studies have identified several other Eda-induced factors that can enhance branching morpho-
genesis such as PTHrP, Egfr ligands, and Wnt pathway agonists34. Hence, the Eda-null and K14-Eda branching 
phenotypes are likely the combinatorial result of changes in the expression level of multiple Eda target genes.
Our data show that Fgf20 has a considerable impact on postnatal mammary morphogenesis since its absence 
led to defective TEB formation and delayed ductal invasion during puberty. However, the ductal growth defect 
was transient: the ductal trees caught up to the WT glands between 7 and 12 weeks of age. We propose that this 
also explains the counterintuitive finding of increased cell proliferation in Fgf20LacZ/LacZ TEBs at 7 weeks of age. In 
WT glands, the percentage of proliferative cells in the TEBs decreases between 3 weeks of age and late puberty (7 
weeks)26, whereas Fgf20LacZ/LacZ mammary glands begin their growth burst at 7 weeks of age.
The embryonic phenotype and the subtle reduction in the number of branches in 3 weeks old Fgf20LacZ/LacZ 
mice implicates that the defect underlying the pubertal ductal phenotype may arise before puberty. We were 
unable to detect Fgf20 expression during puberty, not even by qRT-PCR, a finding in line with a recent study 
assessing Fgf20 expression in mammary glands of 3, 5, and 10 week old mice27. Thus, it is plausible that Fgf20 
deficiency during embryogenesis leads to qualitative changes in the mammary stem/progenitor cells that fully 
manifest only during puberty. Fittingly, a recent study implicated epithelial Fgfr1/2 signaling in proper mammary 
stem cell function during development26. However, we cannot exclude the possibility that Fgf20 is expressed dur-
ing puberty in a rare cell population that escaped our analysis. To answer the question whether Fgf20 has a role 
in pubertal development independent of its embryonic function must await for the generation of a conditional 
Fgf20 mouse.
The mammary phenotype of Fgf20LacZ/LacZ mice resembles the phenotypes generated by K14-Cre-mediated 
deletion of Fgfr126 and MMTV-Cre-mediated (mosaic) deletion of Fgfr224, which both display compromised TEB 
Figure 7. Analysis of terminal end buds of Fgf20LacZ/LacZ mice at 7 weeks of age. (a) Hematoxylin Eosin -stained 
sections of WT and Fgf20LacZ/LacZ TEBs. (b) Quantification of TEB area from Carmine alum stained mammary 
glands of WT (n = 9) and Fgf20LacZ/LacZ (n = 12) mice. (c,c’) Immunohistochemical staining and quantification 
of Ki-67 –positive cells in TEBs of WT (n = 4) and Fgf20LacZ/LacZ (n = 5) mice. Total number of TEBs analyzed 
was n = 26 (WT), n = 30 (Fgf20LacZ/LacZ). (d,d’) Immunohistochemical staining and quantification of cleaved 
caspase-3 –positive cells in WT (n = 4) and Fgf20LacZ/LacZ mice (n = 4). Total number of TEBs analyzed was 
n = 34 (WT), n = 29 (Fgf20LacZ/LacZ). (e–i) Immunohistochemical staining of ERα (e), PR (f), K8 and K14 (g), 
SMAα (h), and p63 (i) in the TEBs of WT and Fgf20LacZ/LacZ mice. Minimum of 4 mice per genotype were 
analyzed. Values represent mean ± SD. **p < 0.01; *p < 0.05; NS, not significant.
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formation, reduced number of branch points, and pubertal ductal outgrowth defect that normalizes in the adult-
hood. A complete failure in TEB maintenance is observed in mice inducibly overexpressing a transgene encoding 
a soluble form of Fgfr2b25. Interestingly, upon cessation of transgene expression 6 weeks after its induction, TEBs 
reform and branching is resumed. These data are suggestive of Fgfr signaling being essential for the functionality 
rather than survival of mammary stem/progenitor cells driving TEB formation and ductal invasion.
Pubertal ductal morphogenesis is a complex hormone regulated process, which involves cellular func-
tions such as proliferation, apoptosis, migration, ECM degradation, and a tight interplay between epithelial 
and mesenchymal compartments6, 15. A great number of genetically manipulated mice, and experiments using 
slowly-releasing protein pellets in vivo, are known to cause a pubertal mammary phenotype23, 44. These studies 
show that loss of tissue integrity in TEBs readily leads to ductal outgrowth defects. However, this is unlikely the 
case in Fgf20LacZ/LacZ mice, as the expression pattern of body and cap cell markers was unaltered. Another impor-
tant class of pubertal phenotypes is caused by loss- or gain-of-function of matrix remodeling enzymes such as 
matrix metalloproteinases (MMPs), which regulate ductal invasion and branching via their ability to sculpt the 
ECM45, 46, and Fgfr1/2 stimulation has been shown to induce the expression of Mmp3 and Mmp9 in several breast 
cancer and immortalized mammary epithelial cell lines47–51.
In conclusion, our results identify a hitherto unknown function for Fgf20 in both embryonic and postnatal 
mammary gland morphogenesis. Our data suggest that compromised Fgf20 signaling during embryogenesis 
results in qualitative changes in TEBs that are thought to harbor the majority of stem cells driving branching mor-
phogenesis during puberty52, 53. To our knowledge, in addition to Fgf1011, Fgf20 is the only Fgf family member 
with a proven in vivo function in mammary gland development. Furthermore, we discovered Fgf20 as an impor-
tant mediator of Eda in mammary gland budding and branching morphogenesis. Future studies should shed light 
on the molecular mechanisms downstream of Fgf20 in mammary gland morphogenesis.
Materials and Methods
Mice. The generation and genotyping of Fgf20LacZ/LacZ, K14-Eda, and Eda−/− (Tabby; Jackson Laboratories, 
stock no 000314) mouse strains have been described previously41, 54. Fgf20LacZ/LacZ and K14-Eda mice were main-
tained in the C57Bl/6 background (K14-Eda > 10 generations and Fgf20LacZ/LacZ > 5 generations) and Eda−/− mice 
in the B6CBA background. Embryonic ages were defined based on the appearance of vaginal plug and external 
criteria including limb morphogenesis55. The sex of embryos older than E14 was defined by PCR with Sry-specific 
primers or anatomy, and only female mice were used for analysis unless otherwise stated. All mouse studies were 
approved and carried out in accordance with the guidelines of the Finnish national animal experimentation 
board.
Embryonic mammary bud cultures and quantitative RT-PCR. The hanging drop culture method 
used for the embryonic mammary bud cultures has been described in detail previously33, 34. Pooled (15–20 buds 
per pool) E13.5 Eda−/− mammary buds were treated with 250 ng/ml of Fc-Eda56 or control medium, RNA was 
extracted, cDNA synthesized, and qRT-PCR performed with the Light Xycler480 machine (Roche, Indianapolis, 
IA) as described33, 34 using the following primers:
Fg f4F  5 ′-CGAGGGACAGTCTTCTGGAG-3 ′ ,  Fg f4R 5 ′-GTACGCGTAGGCTTCGTAGG-3 ′ , 
Fg f9F 5′-GGGGAGCTGTATGGATCAGA-3′, Fg f9R 5′-CTTTGTCAGGGTCCACTGGT-3′ Fg f17F 
5 ′-GACAGATACAT TCGGCAGCA-3 ′ ,  Fg f17R 5 ′-CTGGAAGGCCGTGTAGT TGT-3 ′ ,  Fg f20F 
5′-GTGCCAGGTCCAAAAGACAT-3′, Fgf20R 5′-GGAGAATGATCTTGCTTTGCTT-3′. Dilution series of 
PCR products was used for quantifying the transcript numbers of genes of interest with the help of Lightcycler480 
software. Ranbp1 (F 5′-ACGCTGGAGGAAGATGAAGA-3′, and R 5′-TCATAAGAAGGCGGATGGTC-3′) or 
GAPDH (F 5′-CTCGTCCCGTAGACAAAATGG-3′ and R 5′-AGATGGTGATGGGCTTCCC-3′) were used as 
a reference genes.
X-Gal and Carmine alum staining. X-Gal staining for whole embryos (E10.5–E15.5) or abdominal skins 
of embryos (E16.5–E18) was performed according to a published protocol32 with an overnight incubation in 
the 1 mg/ml X-Gal substrate. For postnatal mammary glands, a modified X-Gal-staining method was used57. 
The X-Gal stained samples were post-fixed with 4% PFA, dehydrated, embedded in paraffin and counterstained 
with nuclear fast red after sectioning. For quantification of mammary ductal ends, the 4th mammary glands and 
surrounding fat pads of E18, 3-, 5-, 7- and 12-week old mice were prepared, spread on slides and subjected to 
Carmine alum staining as previously described34. Quantification of ductal ends, TEBs, and the areas and maxi-
mum widths of TEBs was done manually from images with the help of Fiji ImageJ software. Ductal outgrowth was 
measured as the distance of the furthest grown ductal end from the center of the lymph node.
In situ hybridization. For whole mount in situ hybridization with digoxigenin-labeled RNA probes, E11.5–
E13.75 embryos were fixed in 4% PFA overnight at 4 °C and dehydrated with rising methanol series. In situ 
hybridization was performed with inSituPro robot (Intavis AG) as previously published29, 38 or manually using a 
similar protocol. The digoxigenin-labeled RNA probes for Wnt10b, Edar, Dkk4, Lef1, PTHrP and Fgf20 have been 
described earlier34; Fgf20 probe corresponded to the open reading frame. BM Purple AP substrate Precipitating 
Solution (Boehringer Mannheim) was used for detection of digoxigenin-labeled RNA probes. Radioactive in situ 
hybridization was performed on paraffin sections using 35S-UTP labeled (Amersham) probe specific to Fgf20 as 
described38.
Immunohistochemical stainings. For immunohistochemical and hematoxylin-eosin stainings, the 4th 
mammary glands of WT and Fgf20LacZ/LacZ mice were dissected, spread on microscope slides, and fixed with 4% 
PFA overnight at 4 °C. Alternatively, 13.5 trunks were dissected. The samples were dehydrated, embedded in 
paraffin, and 5 µm sections were cut. Slides were deparaffinized by standard methods. In immunohistochemical 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7: 5049  | DOI:10.1038/s41598-017-04637-1
stainings antigen retrieval was performed by heating the slides in microwave oven in TE buffer, pH 9.0 (keratin-8 
(K8), keratin-14 (K14), progesterone receptor (PR) and estrogen receptor α (ERα) stainings), or in 10 mM 
sodium citrate buffer pH 6.0 (β-Galactosidase, cleaved Caspase-3, Ki-67, α-smooth muscle actin (α-SMA), Lef1, 
and p63 stainings). Primary and secondary antibodies used are listed in Supplementary information. Samples 
were imaged with a Zeiss Axio Imager M2 microscope equipped with an AxioCam HRc camera (Zeiss) and 
processed in Photoshop.
Mammary bud area and volume quantification. Wnt10b expression area was quantified manually from 
images with the help of Fiji ImageJ software. For whole-mount immunofluorescence staining E13.5 and E15.5 
mouse embryos were fixed in 4% PFA at 4 °C overnight. After washing the samples with PBS for 3–4 hours, 
they were permeabilized with 0.3% TritonX-100 in PBS for 1–2 hours at room temperature, blocked (5% nor-
mal donkey serum, 0.5% BSA, and 0.3% TritonX-100 in PBS) for 1 h, and incubated at 4 °C with rat anti-mouse 
CD326 (EpCAM, BD Pharmingen, 552370, 1:1,000) and 10 µg/ml Hoechst 33258 (Molecular Probes/Invitrogen) 
in blocking buffer for 2 days. EpCAM was detected with an Alexa Fluor 647 –conjugated secondary antibody 
(Molecular Probes/Invitrogen). The ventral skin around mammary gland 2 and 3 was dissected and mounted 
with Vectashield (Vector Laboratories) and visualized using a Zeiss LSM700 laser scanning confocal microscope. 
For mammary placode and bud volume quantification, the area of mammary primordium was outlined manually 
based on EpCAM expression and bud morphology. Surface rendering and volume quantification were performed 
with Imaris 8.3 software (Bitplane).
Mammary cell preparation, cell labelling, and flow cytometry. Single cell suspension of mammary 
gland was prepared according to the protocol modified from Shackleton et al.58. Briefly, the 4th mammary glands 
were cut into small pieces after removal of the lymph node. The tissues were digested in a mixture of 5 ml colla-
genase I buffer (10% FBS, 100 mg/ml streptomycin, 10 U/ml penicillin, 300 U/ml collagenase I (ThermoFisher) 
and 100 U/ml hyaluronidase (Sigma) in DMEM/F12 (1:1) medium for 1–2 hours at 37 °C with moderate shaking. 
The cell suspension was washed in PBS and digested further in 0.25% trypsin-EDTA for 5–10 minutes. The red 
blood cells were removed by incubation in red blood cell lysing buffer (Biolegend) on ice for 5 minutes. The single 
cell suspension was passed through 40 µm cell strainer (BD Bioscience) before stained with the mixture of anti-
bodies on ice for 30 minutes. After washing in PBS, the dead cells were labeled with Fixable Viability Dye eFluor 
780 (eBioscience) for 30 minutes on ice. Flow cytometry was carried out by BD LSR II, and data analysis was 
done by Flowjo. The following antibodies were used: CD45-PE (Biolegend, 103106, 1:200), CD31-PE (Biolegend, 
102507, 1:200), TER119-PE (Biolegend, 116207, 1:200) CD24-PeCy7 (Biolegend, 101822, 1:200) and CD29-APC 
(eBioscience, 17–0291–82, 1:200).
Monitoring the onset of puberty, estrous phase, and measurement of estradiol. Onset of 
puberty was assessed by monitoring the vaginal opening (VO) by visual examination of vulva59 every morning 
5 days/week (Mon–Fri) starting at the age of 18 days until the appearance of VO. In case of VO occuring during 
the weekend, the earliest, latest, and average times of VO were defined and separate comparisons of Fgf20LacZ/LacZ 
and WT mice were done using average VO time as well as extreme VO times (eg. VOWTlatest vs. VOFgf20LacZ/LacZ 
earliest and vice versa).
Estrus phase was defined by examining the vaginal cytology collected by vaginal lavage with PBS using a 
small pipet and stained by crystal blue as previously described60. For monitoring the regularity of estrus cycles, 
7-week and 12-week-old Fgf20LacZ/LacZ and WT females were examined 5 days/week in the mornings for at least 
two weeks.
Estradiol levels were measured from serum of 7-week-old mice in diestrus by highly sensitive gas 
chromatography-tandem mass spectrometry61. In case of obtaining zero value from the measurement (n = 3 in 
both WT and Fgf20LacZ/LacZ), value equal to ½ LLOD (lower limit of detection) of estradiol (0.15 pg/ml) was used 
for the sample61. Mice were sacrificed, blood samples were immediately taken by heart puncture and kept over-
night at 4 °C. Mammary glands were used for FACS analysis and immunohistochemistry and uterus and ovaries 
were carefully dissected and weighted. Serum was dissociated the following day by centrifugation in at 3000 rpm 
at 4 °C. Minimum of 250 µl of serum was required for mass spectrometry analysis.
Mammary fat pad transplantations. For mammary fat pad transplantations, 3–4 week old WT (n = 6) 
and Fgf20 LacZ/LacZ (n = 5) recipient females were anesthetized and the fat pad of left 4th mammary gland was 
cleared until the lymph node as described62. ~1 mm3 pieces of adult (12–13-week-old) WT donor (n = 4) mam-
mary glands were transplanted into cleared fat pads. Five weeks later transplanted mammary glands were col-
lected, stained by Carmine alum, and ductal ends quantified.
Statistical analysis. P-values were calculated with unpaired t-test assuming unequal variances unless oth-
erwise stated.
Data availability. The datasets generated during the current study are available from the corresponding 
author on reasonable request.
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